Evidence map›Paper›PMID 32901845›Full record

ArticleMolecular medicine reports2020

Monoclonal antibody against H1N1 influenza virus hemagglutinin cross reacts with hnRNPA1 and hnRNPA2/B1.

Chunyan Guo, Lijun Sun, Shuangping Hao, Xiaoyan Huang, Hanyu Hu, Daoyan Liang, Qing Feng, Yan Li, Yangmeng Feng, Xin Xie and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Chunyan GuoCentral Laboratory of Shaanxi Provincial People's Hospital, The Third Affiliated Hospital of Medical School, Xi'an Jiaotong University, Shaanxi Province Research Centre of Cell Immunological Engineering and Technology, Key Laboratory of Microbial Infections and Autoimmune Diseases, Xi'an, Shaanxi 710068, P.R. China.
Lijun SunCentral Laboratory of Shaanxi Provincial People's Hospital, The Third Affiliated Hospital of Medical School, Xi'an Jiaotong University, Shaanxi Province Research Centre of Cell Immunological Engineering and Technology, Key Laboratory of Microbial Infections and Autoimmune Diseases, Xi'an, Shaanxi 710068, P.R. China.
Shuangping HaoGuangshui Traditional Chinese Medicine Hospital of Hubei Province, Guangshui, Hubei 432700, P.R. China.
Xiaoyan HuangCentral Laboratory of Shaanxi Provincial People's Hospital, The Third Affiliated Hospital of Medical School, Xi'an Jiaotong University, Shaanxi Province Research Centre of Cell Immunological Engineering and Technology, Key Laboratory of Microbial Infections and Autoimmune Diseases, Xi'an, Shaanxi 710068, P.R. China.
Hanyu HuSchool of Public Health and Tropical Medicine, Tulane University, New Orleans, LA 70112, USA.
Daoyan LiangCentral Laboratory of Shaanxi Provincial People's Hospital, The Third Affiliated Hospital of Medical School, Xi'an Jiaotong University, Shaanxi Province Research Centre of Cell Immunological Engineering and Technology, Key Laboratory of Microbial Infections and Autoimmune Diseases, Xi'an, Shaanxi 710068, P.R. China.
Qing FengCentral Laboratory of Shaanxi Provincial People's Hospital, The Third Affiliated Hospital of Medical School, Xi'an Jiaotong University, Shaanxi Province Research Centre of Cell Immunological Engineering and Technology, Key Laboratory of Microbial Infections and Autoimmune Diseases, Xi'an, Shaanxi 710068, P.R. China.
Yan LiCentral Laboratory of Shaanxi Provincial People's Hospital, The Third Affiliated Hospital of Medical School, Xi'an Jiaotong University, Shaanxi Province Research Centre of Cell Immunological Engineering and Technology, Key Laboratory of Microbial Infections and Autoimmune Diseases, Xi'an, Shaanxi 710068, P.R. China.
Yangmeng FengCentral Laboratory of Shaanxi Provincial People's Hospital, The Third Affiliated Hospital of Medical School, Xi'an Jiaotong University, Shaanxi Province Research Centre of Cell Immunological Engineering and Technology, Key Laboratory of Microbial Infections and Autoimmune Diseases, Xi'an, Shaanxi 710068, P.R. China.
Xin XieKey Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Sciences, Northwest University, Xi'an, Shaanxi 710069, P.R. China.
Jun HuCentral Laboratory of Shaanxi Provincial People's Hospital, The Third Affiliated Hospital of Medical School, Xi'an Jiaotong University, Shaanxi Province Research Centre of Cell Immunological Engineering and Technology, Key Laboratory of Microbial Infections and Autoimmune Diseases, Xi'an, Shaanxi 710068, P.R. China.
Shaanxi Provincial People's Hospital · CNHubei Provincial Hospital of Traditional Chinese Medicine · CNNorthwest University · CNTulane University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following influenza A vaccination, certain individuals exhibit adverse reactions in the nervous system, which causes a problem with the safety of the influenza A vaccine. However, to the best of our knowledge, the underlying mechanism of this is unknown. The present study revealed that a monoclonal antibody (H1‑84mAb) against the H1N1 influenza virus hemagglutinin (HA) protein cross‑reacted with an antigen from brain tissue. Total brain tissue protein was immunoprecipitated with this cross‑reactive antibody, and mass spectrometry revealed that the bound antigens were heterogeneous nuclear ribonucleoprotein (hnRNP) A1 and hnRNPA2/B1. Subsequently, the two proteins were expressed in bacteria and it was demonstrated that H1‑84mAb bound to hnRNPA1 and hnRNPA2/B1. These two proteins were expressed in three segments and the cross‑reactivity of H1‑84mAb with the glycine (Gly)‑rich domains of hnRNPA1 (195aa‑320aa) and hnRNPA2/B1 (202aa‑349aa) was determined using ELISA blocking experiments. It was concluded that the Gly‑rich domains of these two proteins are heterophilic antigens that cross‑react with influenza virus HA. The association between the heterophilic antigen Gly‑rich domains and the safety of influenza A vaccines remains to be investigated.

Indexed as

AnimalsAntibodies, MonoclonalBrainHemagglutininsHeterogeneous Nuclear Ribonucleoprotein A1Heterogeneous-Nuclear Ribonucleoprotein Group A-BInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesMaleProtein DomainsRatsAntibodies, MonoclonalHemagglutininsHeterogeneous Nuclear Ribonucleoprotein A1Heterogeneous-Nuclear Ribonucleoprotein Group A-BHnrnpa1 protein, rathnRNP A2Influenza Vaccines

Identifiers

PMID32901845
PMCPMC7533452
OpenAlexW3083018128

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.